5.64 USD
-0.13 (-2.25%)
5.73 USD
+0.09 (+1.6%)
Taking everything into account, MNKD scores 5 out of 10 in our fundamental rating. MNKD was compared to 528 industry peers in the Biotechnology industry. MNKD has only an average score on both its financial health and profitability. MNKD is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year MNKD was profitable.
In the past year MNKD had a positive cash flow from operations.
MNKD had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: MNKD reported negative operating cash flow in multiple years.
1.2 Ratios
MNKD has a Return On Assets of 5.81%. This is amongst the best in the industry. MNKD outperforms 92.23% of its industry peers.
MNKD's Return On Invested Capital of 18.48% is amongst the best of the industry. MNKD outperforms 97.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.81% | ||
| ROE | N/A | ||
| ROIC | 18.48% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 9.16%, MNKD belongs to the top of the industry, outperforming 90.72% of the companies in the same industry.
MNKD has a better Operating Margin (27.48%) than 96.21% of its industry peers.
MNKD's Gross Margin of 78.49% is amongst the best of the industry. MNKD outperforms 84.66% of its industry peers.
MNKD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.48% | ||
| PM (TTM) | 9.16% | ||
| GM | 78.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MNKD is creating value.
Compared to 1 year ago, MNKD has more shares outstanding
The number of shares outstanding for MNKD has been increased compared to 5 years ago.
The debt/assets ratio for MNKD has been reduced compared to a year ago.
2.2 Solvency
MNKD has an Altman-Z score of -5.21. This is a bad value and indicates that MNKD is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.21, MNKD is doing worse than 61.93% of the companies in the same industry.
The Debt to FCF ratio of MNKD is 8.39, which is on the high side as it means it would take MNKD, 8.39 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 8.39, MNKD belongs to the best of the industry, outperforming 91.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 8.39 | ||
| Altman-Z | -5.21 |
ROIC/WACC2.18
WACC8.49%
2.3 Liquidity
A Current Ratio of 3.29 indicates that MNKD has no problem at all paying its short term obligations.
MNKD has a worse Current ratio (3.29) than 60.80% of its industry peers.
A Quick Ratio of 3.04 indicates that MNKD has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.04, MNKD is doing worse than 61.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.04 |
3. Growth
3.1 Past
MNKD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 174.00%, which is quite impressive.
Looking at the last year, MNKD shows a quite strong growth in Revenue. The Revenue has grown by 17.44% in the last year.
The Revenue has been growing by 35.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)174%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%235%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%17.2%
3.2 Future
MNKD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.41% yearly.
Based on estimates for the next years, MNKD will show a quite strong growth in Revenue. The Revenue will grow by 18.41% on average per year.
EPS Next Y-0.55%
EPS Next 2Y17.07%
EPS Next 3Y35.31%
EPS Next 5Y52.41%
Revenue Next Year20.91%
Revenue Next 2Y21.56%
Revenue Next 3Y18.34%
Revenue Next 5Y18.41%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 40.29 indicates a quite expensive valuation of MNKD.
Compared to the rest of the industry, the Price/Earnings ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 91.10% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.30. MNKD is valued slightly more expensive when compared to this.
A Price/Forward Earnings ratio of 51.44 indicates a quite expensive valuation of MNKD.
90.53% of the companies in the same industry are more expensive than MNKD, based on the Price/Forward Earnings ratio.
MNKD's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.04.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.29 | ||
| Fwd PE | 51.44 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MNKD is valued cheaply inside the industry as 94.32% of the companies are valued more expensively.
93.18% of the companies in the same industry are more expensive than MNKD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 39.92 | ||
| EV/EBITDA | 18.04 |
4.3 Compensation for Growth
A more expensive valuation may be justified as MNKD's earnings are expected to grow with 35.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.07%
EPS Next 3Y35.31%
5. Dividend
5.1 Amount
No dividends for MNKD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.64
-0.13 (-2.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners57.07%
Inst Owner Change0.09%
Ins Owners1.59%
Ins Owner Change-1.14%
Market Cap1.73B
Revenue(TTM)313.79M
Net Income(TTM)28.75M
Analysts85.33
Price Target9.24 (63.83%)
Short Float %6.77%
Short Ratio5.56
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)53.26%
Min EPS beat(2)-100%
Max EPS beat(2)206.52%
EPS beat(4)1
Avg EPS beat(4)19.34%
Min EPS beat(4)-100%
Max EPS beat(4)206.52%
EPS beat(8)2
Avg EPS beat(8)-31.68%
EPS beat(12)5
Avg EPS beat(12)-2.87%
EPS beat(16)6
Avg EPS beat(16)-4.99%
Revenue beat(2)1
Avg Revenue beat(2)-2.11%
Min Revenue beat(2)-4.55%
Max Revenue beat(2)0.33%
Revenue beat(4)3
Avg Revenue beat(4)-0.74%
Min Revenue beat(4)-4.55%
Max Revenue beat(4)0.9%
Revenue beat(8)6
Avg Revenue beat(8)1.65%
Revenue beat(12)8
Avg Revenue beat(12)2.45%
Revenue beat(16)11
Avg Revenue beat(16)3.58%
PT rev (1m)0%
PT rev (3m)-14.34%
EPS NQ rev (1m)-11.76%
EPS NQ rev (3m)-42.94%
EPS NY rev (1m)0%
EPS NY rev (3m)-26.21%
Revenue NQ rev (1m)-0.87%
Revenue NQ rev (3m)10.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.29 | ||
| Fwd PE | 51.44 | ||
| P/S | 5.52 | ||
| P/FCF | 39.92 | ||
| P/OCF | 35.45 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 18.04 |
EPS(TTM)0.14
EY2.48%
EPS(NY)0.11
Fwd EY1.94%
FCF(TTM)0.14
FCFY2.51%
OCF(TTM)0.16
OCFY2.82%
SpS1.02
BVpS-0.15
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.81% | ||
| ROE | N/A | ||
| ROCE | 22.37% | ||
| ROIC | 18.48% | ||
| ROICexc | 48.2% | ||
| ROICexgc | 50.4% | ||
| OM | 27.48% | ||
| PM (TTM) | 9.16% | ||
| GM | 78.49% | ||
| FCFM | 13.83% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 8.39 | ||
| Debt/EBITDA | 3.59 | ||
| Cap/Depr | 64.99% | ||
| Cap/Sales | 1.74% | ||
| Interest Coverage | 9.12 | ||
| Cash Conversion | 51.63% | ||
| Profit Quality | 150.89% | ||
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.04 | ||
| Altman-Z | -5.21 |
F-Score8
WACC8.49%
ROIC/WACC2.18
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)174%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%235%
EPS Next Y-0.55%
EPS Next 2Y17.07%
EPS Next 3Y35.31%
EPS Next 5Y52.41%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%17.2%
Revenue Next Year20.91%
Revenue Next 2Y21.56%
Revenue Next 3Y18.34%
Revenue Next 5Y18.41%
EBIT growth 1Y48.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y237.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y386.62%
OCF growth 3YN/A
OCF growth 5YN/A
MANNKIND CORP / MNKD FAQ
What is the fundamental rating for MNKD stock?
ChartMill assigns a fundamental rating of 5 / 10 to MNKD.
Can you provide the valuation status for MANNKIND CORP?
ChartMill assigns a valuation rating of 5 / 10 to MANNKIND CORP (MNKD). This can be considered as Fairly Valued.
Can you provide the profitability details for MANNKIND CORP?
MANNKIND CORP (MNKD) has a profitability rating of 5 / 10.
What are the PE and PB ratios of MANNKIND CORP (MNKD) stock?
The Price/Earnings (PE) ratio for MANNKIND CORP (MNKD) is 40.29 and the Price/Book (PB) ratio is -38.87.